Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: a single institutional review of 70 patients

被引:18
作者
Yang, Liu-song [1 ]
Huang, Feng-ping [1 ]
Zheng, Kang [1 ]
Zhang, Hai-shi [1 ]
Zhou, Xiang [1 ]
Bao, Xu-hui [1 ]
Zheng, Jia-jun [1 ]
Chang, Chuan [1 ]
Zhou, Liang-fu [1 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China
关键词
Anaplastic oligodendroglioma; Intracranial tumor; Prognosis; Survival; GRADE-III; DIAGNOSIS; SURVIVAL; OLIGOASTROCYTOMAS; ASTROCYTOMAS; CHEMOTHERAPY; MANAGEMENT; FEATURES; GLIOMAS; 1P;
D O I
10.1007/s11060-010-0146-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Anaplastic oligodendroglioma (AO) is an uncommon intracranial tumor and prognosis is poor. In this study, we assessed the factors affecting the prognosis of AO patients. Seventy AO patients were recruited from 2001 to 2006 in Shanghai Huashan Hospital of Fudan University; all were treated surgically. Kaplan-Meier survival analysis and Cox regression analysis were used to analyze the prognostic effects of 14 different factors, which were selected from clinical, radiological, pathological, and treatment variables. The results showed that chemotherapy, age, primary or secondary tumors, preoperative Karnofsky Performance Scale (KPS) scores, the presence of epilepsy at initial presentation, radiological contrast infusion, and neurological parameters all correlated with the prognosis of the patients. Furthermore, Cox multivariate analysis also showed that the age (P < 0.048), primary or secondary tumors (P < 0.010), and chemotherapy (P < 0.010) were significantly correlated with the prognosis of the patients. Age and chemotherapy correlated with the prognosis of AO. The patients younger than 50 years old and who received regular chemotherapy were likely to achieve a good outcome. Moreover, individualized treatment after molecular biological typing of AO may improve the prognosis of AO.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 22 条
[1]  
AYMAN A, 2000, AM J CLIN ONCOL-CANC, V23, P170
[2]  
BURGER PC, 1987, CANCER-AM CANCER SOC, V59, P1345, DOI 10.1002/1097-0142(19870401)59:7<1345::AID-CNCR2820590719>3.0.CO
[3]  
2-A
[4]   Oligodendroglioma and anaplastic oligodendroglioma: Clinical features, treatment, and prognosis [J].
Engelhard, HH ;
Stelea, A ;
Mundt, A .
SURGICAL NEUROLOGY, 2003, 60 (05) :443-456
[5]   Oligodendroglioma: Pathology and molecular biology [J].
Engelhard, HH ;
Stelea, A ;
Cochran, EJ ;
Roitberg, B .
SURGICAL NEUROLOGY, 2002, 58 (02) :111-117
[6]   Oligodendroglioma: An appraisal of recent data pertaining to diagnosis and treatment [J].
Fortin, D ;
Cairncross, GJ ;
Hammond, RR .
NEUROSURGERY, 1999, 45 (06) :1279-1291
[7]   Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features [J].
Fuller, CE ;
Schmidt, RE ;
Roth, KA ;
Burger, PC ;
Scheithauer, BW ;
Banerjee, R ;
Trinkaus, K ;
Lytle, R ;
Perry, A .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2003, 62 (11) :1118-1128
[8]   Proposal of a scoring scale as a survival predictor in intracranial oligodendrogliomas [J].
Hamlat, Abderrahmane ;
Saikali, Stephan ;
Chaperon, Jacques ;
Carsin-Nicol, Beatrice ;
Le Calve, Michele ;
Lesimple, Thierry ;
Ben-hassel, Mohamed ;
Guegan, Yvon .
JOURNAL OF NEURO-ONCOLOGY, 2006, 79 (02) :159-168
[9]  
Ino Y, 2001, CLIN CANCER RES, V7, P839
[10]  
KLEIHUES P, 2001, WHO CLASSIFICATION T, P56